Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

@article{GarnockJones2011DabigatranEA,
  title={Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.},
  author={Karly P. Garnock-Jones},
  journal={American journal of cardiovascular drugs : drugs, devices, and other interventions},
  year={2011},
  volume={11 1},
  pages={57-72}
}
The need for safe, effective, and easily administered and monitored antithrombotic treatments that do not have the issues common to warfarin treatment has led to the development of new anticoagulant drugs. Dabigatran etexilate (Pradaxa®, Pradax™) is a prodrug of the direct thrombin inhibitor dabigatran, a direct, reversible, potent inhibitor of thrombin. Dabigatran does not interact with food, and is associated with very few known drug interactions. Dabigatran etexilate, at dosages of 110 and… CONTINUE READING